Advertisement

Organisation › Details
Abivax (Group)
ABIVAX is an advanced clinical development biotech company focused on becoming a global leader in the discovery, development and commercialization of anti-viral drugs and human therapies to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic Hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds and vaccines that may enter the clinical stage in the coming 18 months. ABX464 has been developed using ABIVAX’ anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients’ clear important pathogenic viruses. Headquartered in Paris, France, ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS-Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy. ABIVAX was founded by Dr. Philippe Pouletty, M.D., managing partner at Truffle Capital, the cornerstone investor in ABIVAX since its creation. The company is listed on the regulated market of Euronext Paris, compartment B (ISIN code: FR0012333284 – Ticker: ABVX). *
![]() |
Start | 2013-12-27 merged |
Today | Abivax S.A. (Euronext Paris: ABVX) | |
![]() |
Industry | therapeutic vaccine |
Industry 2 | virostatic agent | |
![]() |
Person | Ehrlich, Hartmut J. (Abivax 201410 CEO before Baxter BioScience 200712 VP Global RnD) |
Person 2 | Kenny, Daniel (Abivax 201410– COO + VP Business Development before Baxter Vaccines + Baxter BioScience) | |
![]() |
Region | Paris |
Country | France | |
Street | 5 rue de la Baume | |
City | 75008 Paris | |
Tel | +33-1-5383-0841 | |
Address record changed: 2017-01-11 | ||
Basic data | Employees | B: 11 to 50 (2014-01-01) |
Currency | EUR | |
Annual sales | 357,000 (income, operating (2017) 2017-12-31) | |
Profit | -11,223,000 (2017-12-31) | |
Cash | 17,032,000 (2017-12-31) | |
* Document for �About Section�: Abivax S.A.. (9/15/15). "Press Release: Abivax Appoints Antonino Ligresti, MD and Dominique Costantini, MD to its Board of Directors". Paris. | ||
Record changed: 2018-09-12 |
Advertisement

More documents for Abivax (Group)
- [1] Abivax S.A.. (12/6/18). "Press Release: Abivax Receives DSMB Recommendation to Continue Ongoing Extension Study of Its Completed Phase 2a Clinical Trial in Ulcerative Colitis patients". Paris....
- [2] Abivax S.A.. (9/4/18). "Press Release: Abivax Reports Impressive Results in Clinical Phase 2a Trial of ABX464 as an Oral Treatment for Ulcerative Colitis Patients". Paris....
- [3] Abivax S.A.. (7/25/18). "Press Release: Abivax Secures up to EUR 20m Debt Financing from Kreos Capital". Paris....
- [4] Abivax S.A.. (6/25/18). "Press Release: Abivax Appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member". Paris....
- [5] Abivax S.A.. (4/9/18). "Press Release: Abivax Strengthens Its Management Team with the Appointment of Alexandra Pearce, Ph.D. as Vice President of Regulatory Affairs". Paris....
- [6] Abivax S.A.. (1/29/18). "Press Release: Abivax Appoints Carol L. Brosgart, M.D. to Its Board of Directors". Paris....
- [7] Abivax S.A.. (12/7/17). "Press Release: Abivax to Present in Plenary Session at the 8th International Conference on HIV Persistence during Therapy". Paris....
- [8] Abivax S.A.. (11/22/17). "Press Release: Abivax to Present at German Equity Forum 2017". Paris....
- [9] Abivax S.A.. (11/20/17). "Press Release: Abivax Enrolls First Ulcerative Colitis Patient in New ABX464 Proof-of-Concept Clinical Trial". Paris....
- [10] Abivax S.A.. (9/28/17). "Press Release: Abivax Secures an Equity Line Financing with Kepler Cheuvreux. Cash for Operations Extended until End of Q2 2019". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top